<DOC>
	<DOCNO>NCT00352105</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Gefitinib may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high-energy x-ray kill tumor cell . Giving cisplatin , fluorouracil , gefitinib together radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect give cisplatin , fluorouracil , gefitinib together hyperfractionated radiation therapy see well work treat patient locally advanced head neck cancer .</brief_summary>
	<brief_title>Cisplatin , Fluorouracil , Iressa , Radiation Therapy Patients With Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Explore activity cisplatin , fluorouracil , gefitinib , hyperfractionated radiotherapy , term 1-year survival 1-year distant metastatic disease control , patient locally advance squamous cell carcinoma head neck . Secondary - Explore activity regimen , term disease-specific survival local control , patient . - Assess toxicity regimen patient . - Assess complete response rate patient treat regimen . - Assess toxicity tolerability long-term maintenance gefitinib patient render disease free treatment regimen . OUTLINE : Patients undergo hyperfractionated radiotherapy twice daily , 5 day week , begin day 1 continue 6 week . Patients also receive fluorouracil IV continuously 96 hour cisplatin IV continuously 96 hour day 1-4 22-25 oral gefitinib begin daily day 1 continue 2 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary* squamous cell carcinoma head neck region , exclude following : Nasopharynx Paranasal sinuses Salivary gland NOTE : *Primary site must identify Locoregionally confined stage III IV disease No evidence nodal disease clavicles No distant hematogenous metastasis ( M0 ) PATIENT CHARACTERISTICS : ECOG performance status 01 WBC &gt; 3,500/mm³ Platelet count &gt; 100,000/mm³ Creatinine ≤ 2.0 mg/dL Alkaline phosphatase &lt; 2 time normal AST &lt; 2 time normal Bilirubin ≤ 2.0 mg/dL Calcium normal Not pregnant nursing Fertile patient must use effective contraception Must poor compliance risk followup No know severe hypersensitivity gefitinib excipients drug No evidence clinically active interstitial lung disease Patients chronic , stable radiographic change asymptomatic eligible No unstable uncontrolled angina , clinically apparent jaundice , active infection No history malignancy ( except squamous cell basal cell skin cancer cervical carcinoma situ ) unless disease free ≥ 5 year No severe , uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) PRIOR CONCURRENT THERAPY : Recovered prior oncologic major surgery No prior definitive surgery , radiotherapy , chemotherapy , immunotherapy , epidermal growth factor receptor inhibitor head neck cancer No investigational drug within past 30 day No concurrent CYP3A4 inducer , include follow : Phenytoin Carbamazepine Rifampin Phenobarbital Hypericum perforatum ( St. John 's wort ) Concurrent surgery allow provide gefitinib administer 2 week 2 week surgery No concurrent aminoglycoside antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>